Prosthetic joint infections: Single versus combination therapy

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 18-23

  Samuel, J R ^a   Gould, F K ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Antagonism; Antimicrobial combinations; Bioavailability; Biofilms; Pharmacokinetics; PJIs; Synergy; Time kill experiments

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; FUSIDATE SODIUM; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; NAFCILLIN; OFLOXACIN; PEFLOXACIN; PENICILLIN DERIVATIVE; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; BLOOD TOXICITY; BONE INFECTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GRAM POSITIVE BACTERIUM; HUMAN; HYPERLACTATEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTIOUS ARTHRITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PROSTHESIS INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA;

EID: 77950365735     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp398     Document Type: Review

References (43)

1. Rober CM, George ME. Principles of anti-infective therapy. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Sixth Edition. Philadelphia, PA, USA: Churchill Livingstone, 2005; 242-53.
2. Watanakunakorn C, Glotzbeker C. Enhancement of the effects of antistaphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother 1974; 6: 802-6.
3. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
4. Barberan J. Management of infections of osteoarticular prosthesis. Clin Microbiol Infect 2006; 12 Suppl 3: 93-101.
5. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350: 1422-9.
6. Widmer AF, Wiestner A, Frei R et al. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991; 35: 741-6.
7. Drancourt M, Stein A, Argenson JN et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-40.
8. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopaedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 1998; 279: 1537-41.
9. Aboltins CAJ, Page MA, Buising KL et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13: 586-91.
10. Drancourt M, Stein A, Argenson JN et al. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopaedic implants. Antimicrob Agents Chemother 1993; 37: 1214-8.
11. Giulieri SG, Graber P, Oschner PE et al. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection 2004; 32: 222-8.
12. Widmer AF, Gaechter A, Oschner PE et al. Antimicrobial treatment of orthopaedic implant-related infections with rifampicin combinations. Clin Infect Dis 1992; 14: 1251-3.
13. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br 2005; 87B: 249-56.
14. Schwank S, Rajacic Z, Zimmerli W et al. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother 1998; 42: 895-8.
15. Stengel D, Bauwens K, Sehouli J et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001; 1: 175-88.
16. Berdal JE, Skramm I, Mowinckel P et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect 2005; 11: 843-5.
17. Gould F, Brindle R, Chadwick P et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus infections in the United Kingdom. J Antimicrob Chemother 2009; 63: 849-61.
18. Bernard L, Hoffmeyer P, Assal M et al. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother 2004; 53: 127-9.
19. Widmer AF. New developments in diagnosis and treatment of infection in orthopaedic implants. Clin Infect Dis 2001; 33 Suppl 2: S94-106.
20. Darley ES, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint infections. Antimicrob Chemother 2004; 53: 928-35.
21. Laffer RR, Graber P, Ochsner PE et al. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin Microbiol Infect 2006; 12: 433-9.
22. Schaad HJ, Chuard C, Vaudaux P et al. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38: 1703-10.
23. LeFrock JL, Ristuccia AM, Ristuccia PA et al. Teicoplanin in the treatment of bone and joint infections. Eur J Surg Suppl 1992; 567:9-13.
24. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55: 387-90.
25. Cepeda JA, Whitehouse T, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53: 345-55.
26. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopaedic infections. Mayo Clin Proc 2004; 9: 1137-44.
27. Nathwani D, Barlow G, Ajdukiewicz K et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother 2003; 51: 391-6.
28. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003; 12: 3173-89.
29. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 4: 425-8.
30. Nathwani D. Health economic issues in the treatment of drug-resistant serious Gram-positive infections. J Infect 2009; 59 Suppl 1: S40-50.
31. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59 Suppl 1: S59-74.
32. Murillo O, Domenech A, Euba G et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008; 57: 229-35.
33. Jacqueline C, Caillon J, Mabecque VL et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-64.
34. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampicin. Pharmacotherapy 2007; 3: 476-9.
35. Saleh-Mghir A, Ameur N, Muller-Serieys C et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 2002; 46: 1122-4.
36. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009; 63: 485-8.
37. Mascio C, Alder J, Silverman J. Bactericidal action of daptomycin against stationary phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007; 51: 4255-60.
38. Raad I, Hannah H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-60.
39. Vaudaux P, Francois P, Bisognano C et al. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003; 52: 89-95.
40. Kennet HR, Herbert JH. Synergy of daptomycin with oxacillin and other b-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 2871-5.
41. Brouqui P, Rousseau M, Stein A et al. Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob Agents Chemother 1995; 39: 2423-5.
42. Riff L, Jackson G. Laboratory and clinical conditions for gentamicin inactivation by carbenecillin. Arch Intern Med 1972; 130: 887-91.
43. Sanginur R, StDenis M, Ferris W et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50: 55-61.